Tilnoprofen arbamel

Drug Profile

Tilnoprofen arbamel

Alternative Names: Y 23023

Latest Information Update: 11 Mar 1996

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Japan Tobacco; Mitsubishi Pharma Corporation
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Opioid analgesics
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain; Rheumatoid arthritis

Most Recent Events

  • 11 Mar 1996 Discontinued-III for Pain in Japan (PO)
  • 11 Mar 1996 Discontinued-III for Rheumatoid arthritis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top